Want to see PRCT full AI Analyst Report?
PRCT Stock Chart & Stats
$25.14
-$0.85(-0.97%)
At close: 4:00 PM EST
$25.14
-$0.85(-0.97%)
Day’s Range― - ―
52-Week Range$19.35 - $62.17
Previous CloseN/A
Volume113.34K
Average Volume (3M)1.57M
Market Cap
$1.19B
Enterprise Value$996.20M
Total Cash (Recent Filing)$245.64M
Total Debt (Recent Filing)$51.66M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Jul 30, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding56,918,842
10 Day Avg. Volume1,458,815
30 Day Avg. Volume1,572,801
Financial Highlights & Ratios
PEG Ratio10.67
Price to Book (P/B)4.78
Price to Sales (P/S)5.67
P/FCF Ratio-29.95
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue3.09
Enterprise Value/Gross Profit4.91
Enterprise Value/Ebitda-10.82
Forecast
1Y Price Target
$29.38Price Target Upside16.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.54
Revenue Forecast (FY)$397.46M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable Revenue StreamA high‑value, per‑procedure consumable (handpiece ASP ≈ $3,500) tied to each case creates a durable recurring revenue stream anchored to installed systems and procedure growth. This improves revenue visibility, drives high incremental margins per case, and underpins long‑term unit economics as procedures scale.
Robust Procedure And Top‑line GrowthSustained double‑digit revenue growth and accelerating procedure volumes indicate meaningful commercial adoption and expanding market penetration. Durable demand growth supports continuous consumable sales, increases installed base monetization, and validates the sales model across regions for the next several quarters.
Improving Gross Margins And Pricing PowerMaterial margin expansion to ~65% reflects better unit economics and product mix, suggesting sustainable operating leverage as volumes rise. Higher gross margins increase scope to fund R&D and commercial expansion while moving towards eventual profitability if revenue growth continues as guided.
Bears Say
Persistent Negative Operating And Free Cash FlowOngoing sizable negative operating and free cash flows mean the business remains dependent on external financing or existing cash to fund growth and trials. Persistent cash burn limits flexibility, raises refinancing risk if markets tighten, and delays self‑funded scaling despite improving trends.
Substantial Operating Losses And Negative MarginsDeep operating and net losses indicate the cost base still outstrips current revenue. Even with revenue growth and margin gains, sustained losses pressure returns on capital, hinder reinvestment efficiency, and mean the path to durable GAAP profitability remains uncertain absent continued rapid revenue scale or cost control.
Rising Operating Expenses And Back‑loaded BenefitsMaterial increases in operating spend to build commercial capacity and fund trials compress near‑term margins and push payoff into the back half of the year. This back‑loaded benefit profile raises execution risk: delayed ramp or slower procedure conversion could extend losses and slow margin realization.
PROCEPT BioRobotics News
PRCT FAQ
What was Procept Biorobotics Corp.’s price range in the past 12 months?
Procept Biorobotics Corp. lowest stock price was $19.35 and its highest was $62.17 in the past 12 months.
What is Procept Biorobotics Corp.’s market cap?
Procept Biorobotics Corp.’s market cap is $1.19B.
When is Procept Biorobotics Corp.’s upcoming earnings report date?
Procept Biorobotics Corp.’s upcoming earnings report date is Jul 30, 2026 which is in 18 days.
How were Procept Biorobotics Corp.’s earnings last quarter?
Procept Biorobotics Corp. released its earnings results on Apr 29, 2026. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.563 by $0.003.
Is Procept Biorobotics Corp. overvalued?
According to Wall Street analysts Procept Biorobotics Corp.’s price is currently Undervalued.
Does Procept Biorobotics Corp. pay dividends?
Procept Biorobotics Corp. does not currently pay dividends.
What is Procept Biorobotics Corp.’s EPS estimate?
Procept Biorobotics Corp.’s EPS estimate is -0.46.
How many shares outstanding does Procept Biorobotics Corp. have?
Procept Biorobotics Corp. has 56,918,842 shares outstanding.
What happened to Procept Biorobotics Corp.’s price movement after its last earnings report?
Procept Biorobotics Corp. reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.563. Following the earnings report the stock price went up 10.732%.
Which hedge fund is a major shareholder of Procept Biorobotics Corp.?
Currently, no hedge funds are holding shares in PRCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PROCEPT BioRobotics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.38 (16.85% Upside)
$29.38 (16.85% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 7.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $18.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.9%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.71%
12-Months-Change
Fundamentals
Return on Equity
-27.70%
Trailing 12-Months
Asset Growth
-6.22%
Trailing 12-Months
Company Description
Procept Biorobotics Corp.
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
PRCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational and commercial trajectory: robust top‑line growth (20% revenue; ~30% procedure growth), margin expansion to management targets (65% gross margin), pricing discipline and meaningful clinical/regulatory wins (EAU guideline upgrade, FDA clearance). These positives are balanced against higher operating expenses, larger GAAP and adjusted EBITDA losses in Q1, tariff headwinds and short‑term disruption from a commercial realignment that push some benefits into the back half of 2026. Management reaffirmed full‑year guidance while taking a prudent near‑term stance, expecting improved leverage and positive EBITDA in Q4.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$29.38
▲(16.85% Upside)
Technical Analysis
Alphatec Holdings
―
Artivion
―
LivaNova
―
Inspire Medical Systems
―
SS Innovations International
―
Ownership Overview
3.00% Insiders
22.48% Mutual Funds
0.10% Other Institutional Investors
57.28% Public Companies and
Individual Investors